PDS Biotechnology Q3 2021 Earnings Report
Key Takeaways
PDS Biotech reported a net loss of $7.0 million, or $(0.24) per basic and diluted share, for the three months ended September 30, 2021. The company's cash and cash equivalents were approximately $69.7 million as of September 30, 2021.
Achieved milestones in the VERSATILE-002 Phase 2 Combination Trial of PDS0101-KEYTRUDA® for recurrent and/or metastatic HPV16-associated head and neck cancer.
Completed a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary TARP tumor antigen for use in PDS0102.
Entered agreement to license COBRA antigens from the University of Georgia for use in the development of PDS0202, a novel Versamune®-based universal flu vaccine.
Announced temporary administrative suspension of enrollment into the NCI-led study of the PDS0101 triple combination.